Multiplex Assay Kit for Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) ,etc. by FLIA (Flow Luminescence Immunoassay) 
GPATC7; GPATCH7; VG5Q; Angiogenic factor VG5Q; G patch domain-containing protein 7; Vasculogenesis gene on 5q protein
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 522.00 US$ 542.00 US$ 572.00 US$ 612.00 US$ 652.00 US$ 712.00 US$ 802.00 US$ 1,003.00
- Quantity
Overview
Properties
- Product No.LML178Ra
- Organism SpeciesRattus norvegicus (Rat) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategorySignal transduction
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) and the recovery rates were calculated by comparing the measured value to the expected amount of Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 87-97 | 93 |
| EDTA plasma(n=5) | 97-104 | 101 |
| heparin plasma(n=5) | 91-98 | 94 |
| sodium citrate plasma(n=5) | 79-90 | 85 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 81-96% | 83-101% | 94-103% | 98-105% |
| EDTA plasma(n=5) | 97-104% | 92-105% | 89-96% | 94-101% |
| heparin plasma(n=5) | 83-90% | 89-101% | 83-105% | 97-105% |
| sodium citrate plasma(n=5) | 94-102% | 90-97% | 89-101% | 88-101% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:AGGF1) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Add 200μL analysis buffer solution to each well of the plate for pre-wetting;
2. Preparation of standards, reagents and samples before the experiment;
3. Add 100μL standard or sample to each well, add 10μL magnetic beads, and incubate 120 minutes protect from light at 25°C on shaker;
4. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60 minutes protect from light at 25°C on shaker;
5. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent B, and incubate 30 minutes protect from light at 25°C on shaker;
6. Wash plate once on magnetic frame;
7. Add 100μL sheath fluid, swirl for 10 minutes, read on the machine.
Test principle
Anti-Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) antibody was coated on the surface of magnetic beads, to make solid phase carrier. Standard or sample were added to the magnetic beads, respectively, in which Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) was bound to the antibody connected to the solid phase carrier, and then biotinylated anti-Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) antibodies were added. PE-labeled avidin was added. There is a positive correlation between the concentration of Angiogenic Factor With G Patch And FHA Domains 1 (AGGF1) in the sample and corresponding value of MFI (Median Fluorescence Intensity).
Giveaways
Increment services
Citations
- Role of microRNA-27a in down-regulation of angiogenic factor AGGF1 under hypoxia associated with high-grade bladder urothelial carcinomaPubmed:24462738
- IL-17 induces macrophages to M2-like phenotype via NF-κBPubmed: 30323677
- Sinoporphyrin Sodium-Mediated Sonodynamic Therapy Inhibits RIP3 Expression and Induces Apoptosis in the H446 Small Cell Lung Cancer Cell LinePubmed: 30562734